Autologous retransplantation for patients with recurrent multiple myeloma

Abstract

Therapeutic options for patients with recurrent multiple myeloma after autologous stem cell transplantation (ASCT) include novel agents, conventional chemotherapy, or salvage ASCT with no standard of care. In the current study, the authors demonstrate that the use of lenalidomide and bortezomib for reinduction has improved the results after salvage ASCT in 200 patients, suggesting that novel agents and salvage ASCT are complementary rather than alternative treatment approaches